Company News

2022
December 14

The Global First ETa-specific Monoclonal Antibody GMA131 was Approved

DKD, as the leading cause of chronic kidney disease and end stage renal disease (ESRD), is one of the most important complications of diabetes. 

2021
November 11

GMAX's GMA106, second generation obesity/T2DM/NASH mAb gives first in

It can be a significant breakthrough as the second generation of drugs in our developmental pipeline for the treatment of obesity and T2DM. 

2021
March 05

GMAX Biopharm International raises USD 78M funding

The financing will help revamp our clinical trials and develop pipeline candidates to produce more innovative medicines for global patients in a much faster speed.

2020
December 15

GMAX Zhengzhou Manufacturing Site Breaks Ground

Gmax Biopharm today holds ground-breaking ceremony for its Zhengzhou, China manufacturing site which is the production base for its GMA102 (T2D), GMA105 (obesity), and GMA301A/B (PAH for adult and children) drugs to be launched between 2023-2025, upon approval of respective clinical trials.

2020
October 24

GMAX Biopharm gives first does of anti-body drug treating PAH in phase

Hangzhou, China. Gmax Biopharm today announces that the first dose of GMA301 was given to the patient in its phase 1B trial to investigate the drug efficacy to treat pulmonary arterial hypertension (PAH).


23 Records 12345